. Author manuscript; available in PMC: 2021 Jul 14.

Published in final edited form as: Bone Marrow Transplant. 2019 Oct 24;55(4):758–762. doi: 10.1038/s41409-019-0725-8

Table 1.

Clinical Characteristics and Outcomes

	A	B	C	D	E	F	G	h	I	J	K	L	M	N	O	P	Q
1		baseline characteristics						donor/graft characteristics			engraftment (days)		GVHD		Follow up		Infections
2	subject number	Age	Sex	Diagnosis	Previous Therapy	HCT-CI	^*ANC on admission cells/μL	Donor relationship	degree of HLA match	infused CD34+ cells/kg (× 10⁶)	Neutrophil	Platelet	aGVHD	cGVHD	alive	follow-up (months)	infectious complications prior to day +100
3	1	39	M	dba	steroids	0	10300	half-brother	haplo	1.54	21	43	none	none	Yes	63	none
4	2	43	M	SAA	ATG/CSA	0	510	brother	haplo	4.86	17	30	S1 skin	none	yes	46	c. diff colitis, BK cystitis
5	3	24	M	SAA	ATG/CSA, promacta	0	3690	sister	haplo	4.05	21	49	none	none	Yes	36	influenza, adenovirus cystitis
6	4	44	F	PNH	steroids, eculizumab	3	2260	sister	full	2.68	16	21	none	moderate eyes	Yes	24	BK cystitis
7	5	42	M	SAA	steroids/ATG/CSA	0	390	cousin	haplo	20.5	18	31	S1 skin	none	Ye	25	bacteremia, BK csystitis
8	6	56	F	SAA	steroids/ATG/CSA	5	2580	unrelated	full	5.65	27	31	none	none	Yes	14	none
9	7	39	M	DBA	steroids, tesosterone	1	6320	cousin	haplo	3.69	21	35	S1 skin	mild eyes	Yes	12	none
10	8	73	M	SAA	ATG/CSA/promacta	0	3580	unrelated	full	4.77	25	57	none	mild eyes	Yes	8	endocarditis
11	9	46	F	SAA	promacta	0	520	cousin	haplo	5.87	17	23	none	none	Yes	4	none

ANC on admission for BMT prior to initiating conditioning chemotherapy

ANC- absolute neutrophil count, SAA- severe aplastic anemia, DBA – Diamond Blackfan Anemia, ATG- anti-thymocyte globulin, CSA-cyclosporine, Cy-cyclophosphamide, haplo- haploidentical